La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Intellia Therapeutics Crescita futura
Future criteri di controllo 2/6
Intellia Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 33.6% e 62.6% all'anno. Si prevede che l'EPS crescerà di 37.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.1% in 3 anni.
Informazioni chiave
33.6%
Tasso di crescita degli utili
37.8%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 30.2% |
Tasso di crescita dei ricavi | 62.6% |
Rendimento futuro del capitale proprio | 4.1% |
Copertura analitica | Good |
Ultimo aggiornamento | 12 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Recent updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | 99 | -595 | -442 | -329 | 18 |
12/31/2025 | 60 | -557 | -430 | -392 | 27 |
12/31/2024 | 55 | -530 | -409 | -383 | 27 |
6/30/2024 | 46 | -509 | -383 | -373 | N/A |
3/31/2024 | 53 | -486 | -418 | -405 | N/A |
12/31/2023 | 36 | -481 | -408 | -394 | N/A |
9/30/2023 | 52 | -462 | -407 | -391 | N/A |
6/30/2023 | 53 | -453 | -384 | -368 | N/A |
3/31/2023 | 53 | -430 | -379 | -363 | N/A |
12/31/2022 | 52 | -474 | -392 | -333 | N/A |
9/30/2022 | 51 | -442 | -355 | -298 | N/A |
6/30/2022 | 45 | -400 | -342 | -285 | N/A |
3/31/2022 | 38 | -369 | -309 | -252 | N/A |
12/31/2021 | 33 | -268 | -238 | -225 | N/A |
9/30/2021 | 27 | -229 | -221 | -211 | N/A |
6/30/2021 | 42 | -185 | -181 | -174 | N/A |
3/31/2021 | 52 | -149 | -69 | -64 | N/A |
12/31/2020 | 58 | -134 | -53 | -50 | N/A |
9/30/2020 | 62 | -120 | -43 | -38 | N/A |
6/30/2020 | 51 | -116 | -41 | -35 | N/A |
3/31/2020 | 46 | -109 | -126 | -120 | N/A |
12/31/2019 | 43 | -100 | -110 | -103 | N/A |
9/30/2019 | 40 | -90 | -89 | -83 | N/A |
6/30/2019 | 37 | -89 | -76 | -70 | N/A |
3/31/2019 | 33 | -86 | -71 | -65 | N/A |
12/31/2018 | 30 | -85 | -68 | -61 | N/A |
9/30/2018 | 29 | -90 | -81 | -74 | N/A |
6/30/2018 | 29 | -83 | -86 | -78 | N/A |
3/31/2018 | 27 | -76 | N/A | -72 | N/A |
12/31/2017 | 26 | -68 | N/A | -65 | N/A |
9/30/2017 | 25 | -54 | N/A | -58 | N/A |
6/30/2017 | 23 | -46 | N/A | -49 | N/A |
3/31/2017 | 21 | -38 | N/A | 34 | N/A |
12/31/2016 | 16 | -32 | N/A | 36 | N/A |
9/30/2016 | 13 | -26 | N/A | 45 | N/A |
6/30/2016 | 9 | -22 | N/A | 49 | N/A |
3/31/2016 | 7 | -18 | N/A | -16 | N/A |
12/31/2015 | 6 | -12 | N/A | -2 | N/A |
9/30/2015 | 4 | -14 | N/A | 1 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che NTLA rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che NTLA rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che NTLA rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di NTLA ( 62.6% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di NTLA ( 62.6% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di NTLA sarà basso tra 3 anni ( 4.1 %).